Intrance Medical Systems, Inc., is a private, U.S.-based biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, South America, Japan and Taiwan. Intrance’s lead product, known as Lecigon® in the European market, is a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The company is rapidly advancing its streamlined U.S. clinical development program in this target indication. Our team is comprised of industry veterans with extensive expertise in advanced Parkinsons disease including proven track records in regulatory, clinical development and commercialization. Intrance is backed by a strong syndicate of investors. The product, which was acquired by a neurology specialty pharma company for commercialization in Europe, has been rapidly gaining market share and user acceptance.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2018
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Intrance Medical Systems founded?
Intrance Medical Systems was founded in 2018.
What industry is Intrance Medical Systems in?
Intrance Medical Systems operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Intrance Medical Systems based?
Intrance Medical Systems is headquartered in New York, United States.
Find investors for your startup like Intrance Medical Systems
Gritt sends AI-personalised outreach to each investor — from your Gmail
